Skip to main content
Fig. 2 | BMC Cardiovascular Disorders

Fig. 2

From: Comprehensive safety profile evaluation of bivalirudin in Chinese ST-segment elevation myocardial infarction patients receiving percutaneous coronary intervention: a prospective, multicenter, intensive monitoring study

Fig. 2

Multivariate logistic regression analysis. Independent risk factors for AEs (A), ADRs (B), thrombocytopenia (C) and bleeding (D) in Chinese STEMI patients receiving PCI and bivalirudin as anticoagulant. AEs: adverse events; ADRs: adverse drug reactions; STEMI: ST-segment elevation myocardial infarction; PCI: percutaneous coronary intervention

Back to article page